Rheum-inations For the physical therapist
|
|
- Walter Lane
- 6 years ago
- Views:
Transcription
1 Rheum-inations For the physical therapist All you wanted to know about rheumatology and more! Susan Shenoi MD, MS, RhMsUS Assistant Professor Clinical Director Seattle Children s Hospital Objectives Case based learning Recognize patterns of joint pain Recognize signs of arthritis Recognize Juvenile Idiopathic Arthritis Categories Medications used Complications Impact exercise on child Brief overview of Juvenile dermatomyositis (JDM) Identify resources for further help Disclosures Pediatric Rheumatology pearls No financial disclosures Will reference off label use of drugs Disclaimer I am not kind enough, not patient enough, not skilled enough..to ever do what you do! Thank you for all that you do to help our kids! Recognize Patterns of Joint Pain
2 ANA leg pain 3 months activity rest Exam normal Labs - not needed If done normal Or + ANA (1:80) Inflammatory AM stiffness/ Gelling Pain better with activity Fatigue +/- Swelling/ Warmth/ Decreased ROM present Examples: JIA, Inflammatory bowel disease related arthritis Mechanical Usually no/ minimal am stiffness Worsening pain with increased activity Lack systemic symptoms like fatigue Swelling/ Warmth/ Decreased ROM +/- Examples: hypermobility, tendonitis, osteoarthritis* ANA body pain 3 months activity rest Pain all day long Pain with light touch Exam normal except for allodynia Labs - normal Or + ANA (1:80) * Seen more commonly in adults ANA leg pain 3 months activity rest such as after sitting for long time Exam shows swollen warm joint(s) that are not moving well Labs ESR and CRP are high Or + ANA (1:640) Central Pain Sensitization Prolonged AM stiffness Pain all over, several days (months/ years) Increasing pain with activity Systemic symptoms, fatigue +, non-restorative sleep Tender points/ Allodynia/ Hyperalgesia Joint exam usually normal no swelling, warmth, normal ROM
3 Rheumatology Pearl #1 Pattern recognition 3 patterns to joint pain: Inflammatory Mechanical ANA leg pain 3 months Waking up at night with pain Fevers on and off Exam arthritis of knee Labs ESR 30 CRP 2.5 CBC platelet 90K WBC 3 K/mm3 Central Pain Sensitization Rheumatology Pearl #2 Arthritis Rheumatology Recognize signs of Arthritis Juvenile arthritis is a diagnosis of exclusion Must rule out infection, malignancies, metabolic, mechanical etc Arthritis = Juvenile Arthritis False arthritis can be secondary to many causes infection, cancers etc Arthritis Rheumatology Malignancy may mimic JIA 21-33% of ALL present with bone pain 62% have musculoskeletal symptoms Examples leukemia, lymphoma, neuroblastoma, localized bone tumors (Ewing's) AVOID STEROIDS TILL DIAGNOSIS CLEAR Jones OY, Pediatrics, 2006
4 When do you suspect it! pain at rest, at night, or out of proportion back pain, bone pain, bone tenderness atypical fevers night sweats weight loss Useful studies low counts (>2 cell lines down) lactate dehydrogenase (LDH), uric acid Imaging (CT chest, abdomen mass/ lymph nodes) BM/ LN biopsy Right hip arthritis/ synovitis Rheumatology referral ROM, pain right hip warmth swelling both ankles Enthesitis (inflammation. tendons, muscle insertion to bone) Plantar fasciitis Diagnosis JIA - Enthesitis related arthritis (ERA) Arthritis = inflammation of joints Recognize Juvenile Arthritis True red, warm, swollen, decreased range of motion Shenoi S. JIA Pediatr Rev May;38(5): Vignette DR 7 yr boy limp for12 months Saw orthopedic 8/15 - X-ray foot and ankle normal - Told limp was behavioral Second opinion - orthopedic 11/15 Decreased range of motion (ROM) hip Inflammatory markers CRP normal (<0.8) ESR 28 (0-10) Blood counts - CBC normal Bone scan normal MRI ankle and pelvis ordered Arthritis is only for old people False kids get arthritis too, CDC 1 in 250 kids have arthritis
5 Rheumatoid Arthritis Adult Juvenile Idiopathic Arthritis < 16 years > 6 weeks duration No known cause Petty R et al. ILAR Classification Edmonton J. Rheum Arthritis in Children JIA is due to vitamin deficiency False we don t know what causes it? Complex Genetic Trait Gene-Environmental Factors Juvenile Arthritis = JCA = JRA = JIA Pathogenesis True one disease many names Other JIA Environment Genes
6 ILAR Classification International League of Associations for Rheumatology 7 mutually exclusive categories: Systemic arthritis Oligoarthritis (persistent, extended) Polyarthritis (RF +)* Polyarthritis (RF -) Psoriatic arthritis Enthesitis-related arthritis Undifferentiated arthritis Petty R et al. ILAR Classification Edmonton J. Rheum Prakken B et al. Lancet 2011 Chronic inflammation: imbalance between mediators Chronic inflammation: Imbalance between mediators TNF IL-1 IL-8 IL-12 IFN IL-1Ra TGF IL-4/IL-13 IL-10 Categories of JIA All juvenile arthritis is the same False 7 categories of JIA different presentations Oligoarticular 4 joints Polyarticular > 4 joints RF(-) Extended oligo > 4 joints RF(+) JIA Systemic-onset Psoriatic arthritis Enthesitis-related Undifferentiated! Image courtesy: Kristin Hayward
7 ANA 3 yr old girl Parents noticed her to be walking limp for 3 months Preschool teachers - she limps too ESR and CRP are normal Polly 2yr girl difficulty running, cranky in morning, swollen fingers, knees, ankles Labs - CRP 15.3 ESR 63 WBC 11.1 HCT 28 Platelet 472 ANA negative RF negative Oligoarticular JIA 40-60% JIA Females 3:1 1-3 years < 5 joints knee, ankle, elbow 70% ANA + 30% asymptomatic uveitis Labs often normal ESR CRP CBC Polyarticular JIA 30-40% JIA Females > 4 joints large and small joints C-Spine, TM joint RF (any age) RF + (10%) usually adolescence 30% ANA Oligoarticular JIA Criteria Exclusions 1-4 joints in first 6 months Persistent -same as above Extended - > 5 joints beyond 6 months Family historypsoriasis Family history-hla B27 disease Positive RF test HLA B27 male with onset >6yrs Systemic features Polyarticular JIA RF Criteria Exclusions 5 or more joints in first 6 months RF - Family historypsoriasis Family history- HLA B27 disease Positive RF test HLA B27 male with onset >6yrs Systemic features
8 Polyarticular JIA RF + Criteria Exclusions 5 or more joints in first 6 months and + RF test twice 3 months apart Family historypsoriasis Family history-hla B27 disease HLA B27 male with onset >6yrs Systemic features Spykar 6 yr boy fevers high spiking 103F X 2 wks Rash on/ off, Recently shortness of breath O/E big liver spleen arthritis Rheumatoid Nodules Micrognathia and Retrognathia Systemic JIA Arthritis with or preceded by fever 2 weeks and any 1 of : -rash -adenopathy -serositis -liver-spleen
9 Systemic JIA 10-20% JIA fevers - daily spike (often pm) to >103F 1/3 pericarditis, pleuritis Adenopathy Hepatosplenomegaly Arthritis variable Evanescent rash in about 80% Anemia, Elevated WBC and platelets Very high ESR, CRP, ferritin ANA, RF negative. Shenoi S, Wallace CA. Diagnosis & Rx of SJIA. J Pediatr Oct;177: Psoriatic JIA Criteria Exclusions Arthritis and psoriasis or Arthritis and two of - Dactylitis - Nail signs -FH Family history- HLA B27 disease Positive RF test HLA B27 male with onset >6yrs Systemic features 9 yr girl swelling of DIP/ PIP hands X 3 mths Silvery scaly rash elbows and scalp BTW mom says always had funny nails Labs at PMD CBC, ESR/ CRP normal, ANA 1:40 Enthesitis Related Arthritis Criteria Exclusions Arthritis and Enthesitis or Arthritis or Enthesitis two of - - Sacroiliac pain - HLA B FH - Anterior uveitis - Male > 6 yrs Family history of psoriasis Systemic features RF + Psoriatic JIA Asymmetric oligoarthritis, DIP joint involvement, dactylitis Uveitis ANA % Enthesitis Related Arthritis Adolescent boys, familial 10-20% Lower extremity oligoarthritis; knees and ankles Spine - Sacroiliitis decreased mobility of the lumbar spine Enthesitis Labs - mildly elevated WBC and ESR RF, ANA - negative. HLA-B27 + > 90%
10 Enthesitis Recognize common medications used to treat JIA Enthesitis There is no cure for arthritis True current therapy controls disease Undifferentiated JIA Criteria Exclusions Not fulfilling criteria for any category Fulfills criteria for more than one category Meeting criteria for other category Rheumatology Pearl #3 JIA requires multidisciplinary management Rheumatology Pharmacologic management PT / OT Ophthalmology Lab/ Radiology Psychosocial support Nutrition and growth. monitoring Pediatrician Nursing support School support Family/ Social support
11 Arthritis can lead to blindness Slit Lamp Exam Chronic Anterior Uveitis True some children have uveitis if untreated can cause blindness ANA positive children more risk regular ophthalmologic screening Rheumatology Pearl #4 Look into the Eyes Besides the PT the ophthalmologist is the rheumatologists best friend! Late Uveitis -Posterior Synechiae Weblike attachment pupillary margin to anterior lens capsule JIA Anterior Uveitis - Asymptomatic Increased risk if ANA+ AAP Guidelines Pediatrics 2006
12 We use chemotherapy to Rx JIA True many medications are known chemotherapeutic meds (methotrexate, cyclosporine, cyclophosphamide) Medications Used - JIA C) Disease Modifying Antirheumatic drugs (DMARDs) Methotrexate (po/ iv/ subcutaneous) Others Sulfasalazine Azathioprine Cyclosporine Hydroxychloroquine Leflunomide Powerful medicines Knowing how and when to use them Medications Used - JIA D) Biologics Anti-TNF Etanercept (Enbrel ), Adalimumab (Humira ) Infliximab (Remicade ), Golimumab (Simponi ), Certolizumab (Cimzia ) Anti-IL1 Anakinra (Kineret ), Canakinumab (Ilaris ), Rilonacept (Arcalyst ) AntiCD20 - Rituximab (Rituxan ) Anti-IL6 - Tocilizumab (Actemra ) CTLA4 - Abatacept (Orencia ) E) Small molecule: JAK kinase inhibitor - Tofacitinib (Xeljanz ) Subcutaneous (SC) Infusion Infusion or sc Oral pill Medications Used - JIA A) Nonsteroidal anti-inflammatory (do not combine) Ibuprofen, Naproxen, Meloxicam, Piroxicam, Diclofenac B) Steroids Prednisolone, IV methylprednisolone, Intraarticular injections triamcinolone acetonide, topical (eyes) Children outgrow their arthritis False it may undergo remission but flares are frequent
13 Children DO NOT outgrow their arthritis 80% of children continue to have active disease Joint damage frequently occurs, and is greatest in the first 2 years of disease 44% achieve remission But by 2 yrs off of meds, most have flared <10% are successfully off meds >5 years Rheumatology Pearl #5 EARLY RECOGNITION IS KEY (you can help!) Once diagnosed early and aggressive therapy improves outcomes! Ringold & Wallace. Rheumatology Early treatment TREAT Inactive disease (ID) and clinical remission on medications are achievable Best chance of achieving Rapid and early initiation of therapy For each month earlier a subject was treated odds ID increased by 1.32; p = Treatment JIA - CARRA Consensus Treatment Plans Childhood Arthritis and Rheumatology Research Alliance North American organization > 400 pediatric rheumatologists, researchers and research coordinators Wallace CA et al. TREAT trial A & R Early treatment ACUTE - JIA Compelling evidence for early aggressive therapy 3 groups: open label study Infliximab and methotrexate Combination DMARD therapy (methotrexate, hydroxychloroquine, sulfasalazine) Methotrexate Response seen in 100% infliximab and methotrexate 65% combination DMARD 50% methotrexate (p<0.0001) Tynjälä P et al. Ann. Rheum. Dis CARRA - CTP Consensus treatment plans (CTP) SJIA Polyarticular JIA Dewitt E et all. AC & R 2012 Ringold S, Shenoi S et al. AC & R 2014 Kimura Y et al. AC & R 2014
14 Polyarticular JIA CTP Other complications of JIA Joint space narrowing Destruction of cartilage Erosions Chronic pain Joint damage Ringold S, Shenoi S et al. AC & R 2014 Recognize common complications JIA Impact Exercise in rheumatic diseases Complications Ana who had OligoJIA is doing well and in remission without active arthritis she still has a gait that is limping and off why? Affected leg grows longer Leg length discrepancy Shoe lift PT = great resource for children with joint pain 100% TRUE
15 How can JIA impact Child Physical pain, weakness, stiffness after sitting, swelling joints, difficulty writing, unable to participate PE, medication side effects (steroids chubby, methotrexate - nausea) Emotional need for chronic medications, long term injections/ infusions, sense of being different from peers, drain on family resources (doctors appts, bills, copay, hospital stays) Education missing school (doctor visits, OT/PT, infusions, flares), difficulty with vision (rarely), completing assignments/ exams (stiff hands) Exercise in JIA Exercise may improve ROM, active joint count, function, QOL & fitness Exercise DOES NOT worsen disease activity or cause flares Intervention trials small to no effect Takken T et al. Eur J Phys Rehab Med 2008;44(3): Cavallo S et al Arch Phys Med Rehabil Dec 6. Exercise can damage the joints False - exercise helps maintain good range of motion - modifications in case of flares Switching gears! Rheumatology Pearl #6 Exercise is the ideal drug Safe Inexpensive Widely available Dose it (pace, self-limit, modify) Houghton K. The Physician and Sports medicine Sep 1;40(3): Hebestreit, H et al. Journal of Rheumatology, (8): p Lelieveld, O.T. et al. Arthritis & Rheumatism, (10): p Henderson, C.J. et al. Arthritis Care & Research, (2): p. 11 Houghton K et al. Journal of Rheumatology, 2013:40(6):979. What is this? 4 year old girl Dermatologist rash on her hands first noticed after she had been swimming did not respond to topical steroids preschool teacher - wasn t keeping up with her classmates parents were complaining she was clumsy
16 Visual diagnosis JDM evaluation Labs: General blood counts, inflammatory markers CPK, aldolase, LDH Antibodies Imaging swallowing study, muscle MRI Electromyogram Muscle biopsy Juvenile dermatomyositis Rash face (includes eyelids) extensor surfaces hands, knees, elbows Muscle weakness proximal more than distal palate, pharynx, proximal esophagus Vasculitis GI tract, skin Treatment of JDM Supportive airway, nutrition Physical Therapy splints, ranging, active strengthening Medications sunscreen steroids (pulse if severe, daily oral) - need prolonged treatment hydroxychloroquine methotrexate, IVIG Cytoxan MMF, cyclosporine Rituximab Identify resources for further help
17 Resources Pediatric Rheumatology Staff Seattle Children s (parents permission) Doctor on call susan.shenoi@seattlechildrens.org Other resources This is a picture of Arthritis Camp in 2010 True Arthritis Foundation This is a picture of Arthritis Camp 1970 s THANK YOU True For the invitation And your attention
18 AND MY HOPE... Too late is the medicine prepared, when the disease has gained strength by long delay Questions
Etiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis
Etiology: Pathogenesis Clinical manifestation Investigation Treatment Prognosis JIA is the most common rheumatic disease in childhood and a major cause of chronic disability. Etiology: Unknown, but may
More informationJuvenile Idiopathic Arthritis (JIA)
Juvenile Idiopathic Arthritis (JIA) Kaveh Ardalan, MD, MS Division of Rheumatology Ann & Robert H. Lurie Children s Hospital of Chicago Assistant Professor, Pediatrics and Medical Social Sciences Northwestern
More informationJIA and Other Rheumatic Diseases in Children. Norma Liburd, RN-BC, MN
JIA and Other Rheumatic Diseases in Children Norma Liburd, RN-BC, MN Define Juvenile Idiopathic Arthritis (JIA) and discuss the diagnostic criteria. Objectives Identify the subtypes of JIA and discuss
More informationJuvenileIdiopathicArthritis. Dr Johan Siebert
JuvenileIdiopathicArthritis Dr Johan Siebert 1 NORMAL DIARTHRODIAL JOINT Synovial is a thin membrane enclosing the joint space The joint space contains fluid that bathes the joint and reduces friction
More informationEffective Health Care Program
Comparative Effectiveness Review Number 28 Effective Health Care Program Disease-Modifying Antirheumatic Drugs (DMARDs) in Children With Juvenile Idiopathic Arthritis (JIA) Executive Summary Background
More informationDepartment of Paediatrics Clinical Guideline. Guideline for the child with possible arthritis (joint swelling/pain, loss of function)
Department of Paediatrics Clinical Guideline Guideline for the child with possible arthritis (joint swelling/pain, loss of function) Definition: Juvenile Idiopathic Arthritis (JIA) is defined as arthritis
More informationMore Than Growing Pains: Therapeutic Review of Juvenile Idiopathic Arthritis (JIA)
More Than Growing Pains: Therapeutic Review of Juvenile Idiopathic Arthritis (JIA) Brittany A. Bruch, PharmD PGY2 Ambulatory Care Pharmacy Resident University of Iowa Hospitals and Clinics November 10,
More information1 P a g e. Systemic Juvenile Idiopathic Arthritis (SJIA) (1.3) Patients 2 years of age and older with active systemic juvenile idiopathic arthritis.
LENGTH OF AUTHORIZATION: Initial: 3 months for Crohn s or Ulcerative Colitis; 1 year for all other indications. Renewal: 1 year dependent upon medical records supporting response to therapy and review
More informationRheumatoid arthritis and Psoriatic arthritis: a guide for Primary Care. Nina Flavin, MD Rheumatology Confluence Health April 13 th, 2018
Rheumatoid arthritis and Psoriatic arthritis: a guide for Primary Care Nina Flavin, MD Rheumatology Confluence Health April 13 th, 2018 No Disclosures Objectives Recognize early signs of RA/PsA what to
More informationRHEUMATOLOGY OVERVIEW. Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center
RHEUMATOLOGY OVERVIEW Carmelita J. Colbert, MD Assistant Professor of Medicine Division of Rheumatology Loyola University Medical Center What is Rheumatology? Medical science devoted to the rheumatic diseases
More informationSeronegative Arthritis. Dr Mary Gayed 25 th April 2018
Seronegative Arthritis Dr Mary Gayed 25 th April 2018 Overview Description of the conditions Discussion of symptoms & investigations that may be required Discussion of management and treatment Questions
More informationRheumatoid Arthritis
Rheumatoid Arthritis What is rheumatoid arthritis? Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Rheumatoid arthritis can also cause inflammation of
More informationWelcome to today s webinar. Juvenile Arthritis Webinar. Arthritis Foundation. What is arthritis? 12/16/2014
Welcome to today s webinar This program is supported by generous grants from: AbbVie & Genentech Juvenile Arthritis Webinar Arthritis Foundation JIA 101 : An overview of juvenile idiopathic arthritis and
More informationIntroduction. Rheumatoid Arthritis. Rheumatoid Arthritis. Arthritis vs Rheumatoid Arthritis
Rheumatoid Arthritis Stuart Weisman, MD Boulder Medical Center, P.C. 303-622-3724 Introduction What is rheumatoid arthritis? How is it different than arthritis? What are the symptoms? How is it diagnosed?
More informationDrug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases
Drug Class Prior Authorization Criteria Therapeutic Agents in Rheumatic and Inflammatory Diseases Line of Business: Medicaid P & T Approval Date: August 16, 2017 Effective Date: August 16, 2017 This policy
More informationFirst Name. Specialty: Fax. First Name DOB: Duration:
Prescriber Information Last ame: First ame DEA/PI: Specialty: Phone - - Fax - - Member Information Last ame: First ame Member ID umber DOB: - - Medication Information: Drug ame and Strength: Diagnosis:
More informationPatient #1. Rheumatoid Arthritis. Rheumatoid Arthritis. 45 y/o female Morning stiffness in her joints >1 hour
Patient #1 Rheumatoid Arthritis Essentials For The Family Medicine Physician 45 y/o female Morning stiffness in her joints >1 hour Hands, Wrists, Knees, Ankles, Feet Polyarticular, symmetrical swelling
More informationRHEUMATOID ARTHRITIS DRUGS
Rheumatology Biologics Criteria from the Exceptional Access Program RHEUMATOID ARTHRITIS DRUGS DRUG NAME BRS REIMBURSED DOSAGE FORM/ STRENGTH Adalimumab Humira 40 mg/0.8 syringe and 40mg/0.8 pen for Anakinra
More informationOtezla. Otezla (apremilast) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Otezla Page: 1 of 5 Last Review Date: March 16, 2018 Otezla Description Otezla (apremilast) Background
More informationDepartment of Paediatrics Clinical Guideline
Department of Paediatrics Clinical Guideline The child and young person with possible arthritis (joint swelling and/or pain, loss of function for >4 weeks) Definition: Juvenile Idiopathic Arthritis (JIA)
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 9 Last Review Date: March 16, 2018 Simponi / Simponi
More informationA Patient s Guide to Psoriatic Arthritis
A Patient s Guide to Psoriatic Arthritis Glendale Adventist Medical Center 1509 Wilson Terrace Glendale, CA 91206 Phone: (818) 409-8000 DISCLAIMER: The information in this booklet is compiled from a variety
More informationA Patient s Guide to. Treatments for Psoriatic Arthritis
A Patient s Guide to Treatments for Psoriatic Arthritis Who should read this guide? This guide is aimed at people with psoriatic arthritis (abbreviated as PsA), or those who care for a person with this
More informationUnderstanding Rheumatoid Arthritis
Understanding Rheumatoid Arthritis Understanding Rheumatoid Arthritis What Is Rheumatoid Arthritis? 1,2 Rheumatoid arthritis (RA) is a chronic autoimmune disease. It causes joints to swell and can result
More informationArthritis Foundation Education Series. Juvenile Arthritis. Symptoms, diagnosis and treatment
Arthritis Foundation Education Series Juvenile Arthritis Symptoms, diagnosis and treatment UNDERSTANDING JUVENILE ARTHRITIS People of all ages can and do have arthritis. Nearly 300,000 children from infants
More informationOverview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology
Overview of Paediatric Investigation Plan (PIP) in Paediatric Rheumatology Paediatric Rheumatology Expert Meeting, London 4 th December 29 Dr. Richard Veselý, Dr. Emma Sala Soriano Paediatric Investigation
More informationJuvenile Spondyloarthritis / Enthesitis Related Arthritis (SpA-ERA)
www.printo.it/pediatric-rheumatology/gb/intro Juvenile Spondyloarthritis / Enthesitis Related Arthritis (SpA-ERA) Version of 2016 1. WHAT IS JUVENILE SPONDYLOARTHRITIS/ENTHESITIS- RELATED ARTHRITIS (SpA-ERA)
More informationCimzia. Cimzia (certolizumab pegol) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.50.11 Section: Prescription Drugs Effective Date: April 1, 2018 Subject: Cimzia Page: 1 of 5 Last Review
More informationCorporate Medical Policy
Corporate Medical Policy File Name: Origination: Last CAP Review: Next CAP Review: Last Review: abatacept_orencia 4/2008 2/2018 2/2019 2/2018 Description of Procedure or Service Abatacept (Orencia ), a
More informationUnderstanding Arthritis. Training
Understanding Arthritis Training 1 Learning Objectives At the end of this training the learner will: Be able to define Arthritis Describe the symptoms of Arthritis Understand the impact of Arthritis Know
More informationTHE MANAGEMENT OF JUVENILE IDIOPATHIC ARTHRITIS
THE MANAGEMENT OF JUVENILE IDIOPATHIC ARTHRITIS Prof Chris Scott PAEDIATRIC RHEUMATOLOGIST UNIVERSITY OF CAPE TOWN RED CROSS WAR MEMORIAL CHILDRENS S HOSPITAL Chronic Arthritis >6wks JIA No other cause
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell costimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.18 Subject: Orencia Page: 1 of 8 Last Review Date: March 16, 2018 Orencia Description Orencia (abatacept)
More informationRheumatoid Arthritis. Rheumatoid Arthritis. RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling. Rheumatic Diseases
RCS 6080 Medical and Psychosocial Aspects of Rehabilitation Counseling Rheumatic Diseases The prevalence of rheumatoid arthritis in most Caucasian populations approaches 1% among adults 18 and over and
More informationCanadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC
Canadian Society of Internal Medicine Annual Meeting 2016 Montreal, QC Update on the Treatment of Rheumatoid Arthritis Sabrina Fallavollita MDCM McGill University Canadian Society of Internal Medicine
More informationSubject: Remicade (Page 1 of 5)
Subject: Remicade (Page 1 of 5) Objective: I. To ensure that Health Share/Tuality Health Alliance (THA) has a process by which the appropriate utilization of Remicade (Infliximab) for members whose diagnosis
More informationDrugs and Applicable Coding: J-code: Enbrel-J1438; Humira-J0135; Remicade-J1745; Inflectra-Q5102; Cimzia-J0718; Simponi-J1602 Renflexis - pending
Policy Subject: Anti-TNF Agents Policy Number: SHS PBD16 Category: Rheumatology & Autoimmune Policy Type: Medical Pharmacy Department: Pharmacy Product (check all that apply): Group HMO/POS Individual
More informationRheumatoid arthritis
Rheumatoid arthritis 1 Definition Rheumatoid arthritis is one of the most common inflammatory disorders affecting the population worldwide. It is a systemic inflammatory disease which affects not only
More informationRegulatory Status FDA-approved indication: Orencia is a selective T cell co-stimulation modulator indicated for: (1)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 Subject: Orencia Page: 1 of 9 Last Review Date: September 20, 2018 Orencia Description Orencia (abatacept)
More informationCoverage Criteria: Express Scripts, Inc. monograph dated 12/15/ months or as otherwise noted by indication
BENEFIT DESCRIPTION AND LIMITATIONS OF COVERAGE ITEM: PRODUCT LINES: COVERED UNDER: DESCRIPTION: CPT/HCPCS Code: Company Supplying: Setting: Kineret (anakinra subcutaneous injection) Commercial HMO/PPO/CDHP
More informationORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
UnitedHealthcare Community Plan Medical Benefit Drug Policy ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION Policy Number: CS2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationImmune Modulating Drugs Prior Authorization Request Form
Patient: HPHC member ID #: Requesting provider: Phone: Servicing provider: Diagnosis: Contact for questions (name and phone #): Projected start and end date for requested Requesting provider NPI: Fax:
More informationMary Derlacki, FNP. No financial relationships to disclose. Office Rheumatology for the Nurse Practitioner. Rheumatoid Arthritis
Office Rheumatology for the Nurse Practitioner Mary Derlacki, FNP Drs. Cassell and Boren Eugene, OR 541-687-0816 mderlacki@comcast.net No financial relationships to disclose Rheumatoid Arthritis 1% of
More informationPsoriatic Arthritis Shared Decision Making
Psoriatic Arthritis Shared Decision Making Disease Modifying Drug Therapy DMARDs Therapy El Miedany et al. Ann Rheum Dis 74(Suppl2): 1002 DOI: 10.1136/annrheumdis-2015-eular.1410 www.rheumatology4u.com
More informationwww.fisiokinesiterapia.biz Peak onset between 20 and 30 years Form of spondyloarthritis (cause inflammation around site of ligament insertion into bone) and association with HLA-B27 Prevalence as high
More informationMedication Policy Manual. Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013
Medication Policy Manual Policy No: dru289 Topic: Xeljanz, tofacitinib Date of Origin: January 21, 2013 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1,
More informationJUVENILE IDIOPATHIC ARTHRITIS A case based study. By: Michael Zhanel. Home for the Summer Program July to August, 2018.
JUVENILE IDIOPATHIC ARTHRITIS A case based study By: Michael Zhanel Home for the Summer Program July to August, 2018 Oakbank, Manitoba Supervisor: Dr. Nader Shenouda Abstract Juvenile idiopathic arthritis
More informationXeljanz. Xeljanz, Xeljanz XR (tofacitinib) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.24 Subject: Xeljanz Page: 1 of 6 Last Review Date: March 16, 2018 Xeljanz Description Xeljanz, Xeljanz
More informationSafety profiles of agents used in the treatment of JIA
Safety profiles of agents used in the treatment of JIA Sampath Prahalad, MD, MSc Marcus Professor of Pediatric Rheumatology Chief, Division of Pediatric Rheumatology Emory University School Of Medicine
More informationBiologics for Autoimmune Diseases
Biologics for Autoimmune Diseases Goal(s): Restrict use of biologics to OHP funded conditions and according to OHP guidelines for use. Promote use that is consistent with national clinical practice guidelines
More information8/29/2012. Outline Juvenile idiopathic arthritis. 1. Classification-ILAR. 1. Classification-clinical diagnosis. 1. JIA classification
Outline Juvenile idiopathic arthritis 1. Classification and symptoms (ILAR-International league of Associations for Rheumatology) 2. Imaging J. Herman Kan, M.D. Section chief, musculoskeletal imaging Edward
More informationRheumatoid Arthritis. By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University
Rheumatoid Arthritis By: Hadi Esmaily (PharmD., BCCP, MBA) Department of Clinical Pharmacy, Shahid Beheshti Medical University Introduction RA is a Chronic, Systemic, Inflammatory disorder of unknown etiology
More informationINFLIXIMAB Remicade (infliximab), Inflectra (infliximab-dyyb), Ixifi* (infliximabqbtx), Renflexis (infliximab-abda)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 6 years of age or older 1. Moderate to severe Crohn s disease (CD) a. Patient has fistulizing disease
More informationKEEP UP THE FIGHT WITH. Little Victories
FOR MODERATE TO SEVERE RHEUMATOID ARTHRITIS (RA) KEEP UP THE FIGHT WITH Little Victories Small improvements in your daily activities may be a sign that ORENCIA (abatacept) is working for you. Use this
More informationACTEMRA (tocilizumab)
Pre - PA Allowance None Prior-Approval Requirements Diagnoses Patient must have ONE of the following: 1. Active Polyarticular Juvenile Idiopathic Arthritis (PJIA) b. Patient has an intolerance or has experienced
More informationDr Daniel Ching. Rheumatology Therapeutic Clinical Trials Centre Timaru
Dr Daniel Ching Rheumatology Therapeutic Clinical Trials Centre Timaru Therapeutic Advances in Rheumatology GP CME Meeting, Dunedin, 18.08.2013 Dr Daniel Ching, MB FRCP FRACP Consultant Rheumatologist,
More informationUpdate on Enthesitis-Related Arthritis, a Subtype of Juvenile Idiopathic Arthritis
Hong Kong Bull Rheum Dis 2010;10:15-19 Review Article Update on Enthesitis-Related Arthritis, a Subtype of Juvenile Idiopathic Arthritis Tsz-Leung Lee Abstract: Keywords: Enthesitis related arthritis (ERA)
More informationRheumatoid Arthritis Update. Whitney White, Pharm.D., BCPS Associate Professor of Pharmacy Practice Samford University McWhorter School of Pharmacy
Rheumatoid Arthritis Update Whitney White, Pharm.D., BCPS Associate Professor of Pharmacy Practice Samford University McWhorter School of Pharmacy Disclosures I declare that neither I nor any member of
More informationMMS Pharmacology Lecture 2. Antirheumatic drugs. Dr Sura Al Zoubi
MMS Pharmacology Lecture 2 Antirheumatic drugs Dr Sura Al Zoubi Revision Rheumatoid Arthritis Definition (RA): is the most common systemic inflammatory disease characterized by symmetrical inflammation
More informationPyrexia of unknown origin? Think still
Pyrexia of unknown origin? Think still Lawrence Owino Okong o, Mmed (UoN); Mphil. (UCT). Lecturer, Department of Paediatrics and Child Health, University of Nairobi. Paediatrician/ Rheumatologist. DISCLAIMER
More informationRheumatology 101 A Pediatrician s Guide
Rheumatology 101 A Pediatrician s Guide Pediatric Staff and Alumni Day 2016 Dawn M. Wahezi, Yonit Sterba, Tamar Rubinstein Disclosures None Pick a Group Group 1 A child with a limp Group 2 ANA To test
More informationAccording to the International League of Associations. Juvenile Idiopathic Arthritis. An Update for the Clinician. Philip Kahn, M.D.
152 Juvenile Idiopathic Arthritis An Update for the Clinician Philip Kahn, M.D. Abstract Juvenile idiopathic arthritis (JIA) comprises a collection of all forms of chronic arthritis in childhood with no
More informationMedical Policy An independent licensee of the Blue Cross Blue Shield Association
Otezla (apremilast) Page 1 of 7 Medical Policy An independent licensee of the Blue Cross Blue Shield Association Title: Otezla (apremilast) Prime Therapeutics will review Prior Authorization requests Prior
More informationHARVARD PILGRIM HEALTH CARE RECOMMENDED MEDICATION REQUEST GUIDELINES HUMIRA PEDIATRIC
Generic Brand HICL GCN Exception/Other ADALIMUMAB HUMIRA 24800 HUMIRA PEDIATRIC GUIDELINES FOR USE INITIAL CRITERIA (NOTE: FOR RENEWAL CRITERIA SEE BELOW) 1. Is the patient currently taking Humira? If
More informationMedication Policy Manual. Topic: Otezla, apremilast Date of Origin: May 9, 2014
Medication Policy Manual Policy No: dru342 Topic: Otezla, apremilast Date of Origin: May 9, 2014 Committee Approval Date: January 19, 2015 Next Review Date: January 2016 Effective Date: April 1, 2015 IMPORTANT
More informationORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION
ORENCIA (ABATACEPT) INJECTION FOR INTRAVENOUS INFUSION UnitedHealthcare Commercial Medical Benefit Drug Policy Policy Number: 2018D0039J Effective Date: March 1, 2018 Table of Contents Page INSTRUCTIONS
More informationPharmacy Management Drug Policy
SUBJECT: Inflammatory Conditions Clinical Review Prior Authorization (CRPA) Rx and Medical Drugs POLICY NUMBER: PHARMACY-73 EFFECTIVE DATE: 01/01/2018 LAST REVIEW DATE: 06/11/2018 If the member s subscriber
More informationEarly synovitis clinics
Early synovitis clinics Jeremy Jones MD FRACP FAFRM Consultant Rheumatologist, Llandudno General Hospital Honorary Research Fellow School of Sport, Health and Exercise Sciences Bangor University RA medication
More informationCenter for Evidence-based Policy
P&T Committee Brief Targeted Immune Modulators: Comparative Drug Class Review Alison Little, MD Center for Evidence-based Policy Oregon Health & Science University 3455 SW US Veterans Hospital Road, SN-4N
More informationSteps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS
Moderate to Severe Rheumatoid Arthritis (RA) 3 Steps TO HELP YOU TALK WITH YOUR DOCTOR ABOUT YOUR TREATMENT OPTIONS INDICATION/USAGE Adult Rheumatoid Arthritis (RA): ORENCIA (abatacept) is a prescription
More informationRegulatory Status FDA- approved indication: Simponi and Simponi ARIA are tumor necrosis factor (TNF) blockers indicated for the treatment of:
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.51 Subject: Simponi / Simponi ARIA Page: 1 of 8 Last Review Date: March 17, 2017 Simponi / Simponi
More informationACTEMRA (TOCILIZUMAB) INJECTION FOR INTRAVENOUS INFUSION
ACTEMRA (TOCILIZUMAB) INJECTION FOR INTRAVENOUS INFUSION UnitedHealthcare Oxford Clinical Policy Policy Number: PHARMACY 284.9 T2 Effective Date: June 1, 2018 Table of Contents Page INSTRUCTIONS FOR USE...
More informationStelara. Stelara (ustekinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.04 Subject: Stelara Page: 1 of 9 Last Review Date: September 20, 2018 Stelara Description Stelara
More informationThe ORENCIA (abatacept) JIA Observational Registry
Moderate to Severe Juvenile Idiopathic Arthritis (JIA) Injection for Intravenous Use Injection for Subcutaneous Use The ORENCIA (abatacept) JIA Observational Registry Injection for Intravenous Use Injection
More informationObjectives. Joint Pain. Case 1. Rheumatology for the Primary MD (Not just your grandmother s disease) 12/4/2010
Objectives Rheumatology for the Primary MD (Not just your grandmother s disease) Identify when it is appropriate to refer for rheumatologic evaluation Autoimmune/ Inflammatory v. noninflammatory disease
More informationPain or stiffness in joints after periods of inactivity or excessive use
Arthritis Awareness* Some older adults call it Arthur ; others refer to it as their constant compassion, but most describe it as extremely painful Arthritis is a chronic joint disease It is commonly believed
More informationRheumatoid Arthritis. Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011
Rheumatoid Arthritis Marge Beckman FALU, FLMI Vice President RGA Underwriting Quarterly Underwriting Meeting March 24, 2011 The security of experience. The power of innovation. www.rgare.com Case Study
More informationPractical RA Treatment: James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014
Practical RA Treatment: 2014 James R. O Dell, M.D. University of Nebraska Medical Center May 24, 2014 Disclosures James R. O Dell PI of Multinational RA trial supported by VA and NIH (NIAMS) that receives
More information2/23/18. Disclosures. Rheumatic Diseases of Childhood. Making Room for Rheumatology. I have nothing to disclose. James J.
Making Room for Rheumatology James J. Nocton, MD Disclosures I have nothing to disclose Rheumatic Diseases of Childhood Juvenile Idiopathic Arthritis (JIA) Systemic Lupus Erythematosus (SLE) Juvenile Dermatomyositis
More informationHorizon Scanning Technology Summary. Abatacept (Orencia) for juvenile idiopathic arthritis. National Horizon Scanning Centre.
Horizon Scanning Technology Summary National Horizon Scanning Centre Abatacept (Orencia) for juvenile idiopathic arthritis June 2007 This technology summary is based on information available at the time
More informationFml Limits. Azathioprine (Imuran) 50mg, 75mg, 100mg - $26.85 Cyclosporine, 25mg, 100mg. $ Leflunomide (Arava) 10mg Tablet - $144.
MEDICATION COVERAGE POLICY PHARMACY AND THERAPEUTICS ADVISORY COMMITTEE POLICY: Rheumatoid Arthritis (RA) P&T DATE: 2/15/2017 CLASS: Rheumatology/Anti-inflammatory Disorders REVIEW HISTORY 2/16, 5/15,
More informationActemra. Actemra (tocilizumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.12 Subject: Actemra Page: 1 of 13 Last Review Date: September 20, 2018 Actemra Description Actemra
More informationRheumatoid Arthritis
Rheumatoid Arthritis Rheumatoid arthritis (RA) is an autoimmune disease that causes chronic inflammation of the joints. Autoimmune diseases are illnesses that occur when the body's tissues are mistakenly
More informationRemicade (Infliximab)
Remicade (Infliximab) Policy Number: Original Effective Date: MM.04.016 11/18/2003 Line(s) of Business: Current Effective Date: HMO; PPO; QUEST Integration 07/26/2013 Section: Prescription Drugs Place(s)
More informationCosentyx. Cosentyx (secukinumab) Description
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.90.11 Subject: Cosentyx Page: 1 of 7 Last Review Date: September 20, 2018 Cosentyx Description Cosentyx
More informationJuvenile idiopathic arthritis managed in the new millennium: one year outcomes of an inception cohort of Australian children
Tiller et al. Pediatric Rheumatology (2018) 16:69 https://doi.org/10.1186/s12969-018-0288-z RESEARCH ARTICLE Open Access Juvenile idiopathic arthritis managed in the new millennium: one year outcomes of
More informationCIMZIA (certolizumab pegol)
Pre - PA Allowance None Prior-Approval Requirements Age Diagnoses 18 years of age or older Patient must have ONE of the following: 1. Moderate to severe Crohn s Disease (CD) a. Inadequate response, intolerance
More informationDr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria
Dr. Lyubomir Marinchev Chief of Rheumatology Department, MHAT SOFIAMED, Sofia, Bulgaria Inter-Balkan meeting Open the frontiers and exchange of experiences, 27 th April 2013, Rhodes, Greece Patients with
More informationRheumatology Review Update in Internal Medicine COPYRIGHT. Robert H. Shmerling, M.D. Beth Israel Deaconess Medical Center.
Rheumatology Review Update in Internal Medicine Robert H. Shmerling, M.D. Beth Israel Deaconess Medical Center Boston MA Case #1 True statement(s) regarding etanercept and leflunomide, for the treatment
More informationJuvenile Idiopathic Arthritis
https://www.printo.it/pediatric-rheumatology/ie/intro Juvenile Idiopathic Arthritis Version of 2016 1. WHAT IS JIA 1.1 What is it? Juvenile idiopathic arthritis (JIA) is a chronic disease characterised
More informationEARLY INFLAMMATORY ARTHRITIS. Cristina Tacu Consultant Rheumatologist Brighton and Sussex University Hospital
EARLY INFLAMMATORY ARTHRITIS Cristina Tacu Consultant Rheumatologist Brighton and Sussex University Hospital EIA: Introduction National priority Preventable cause of disability Very common condition High
More informationRheumatoid Arthritis Fact Sheet
Rheumatoid Arthritis Fact Sheet This fact sheet is a summary of information found on ra.org.nz. Remember that each person is different and you should talk to your doctor about your disease and the best
More informationBACK FIGHT. It s time to. Take action today. Ask your rheumatologist about ORENCIA.
For moderate to severe Rheumatoid Arthritis (RA) It s time to FIGHT BACK Model, not actual patient. Take action today. Ask your rheumatologist about ORENCIA. What is ORENCIA? ORENCIA (abatacept) is a prescription
More informationRegulatory Status FDA-approved indication: Enbrel and Erelzi are tumor necrosis factor (TNF) blockers indicated for the treatment of: (2-3)
Federal Employee Program 1310 G Street, N.W. Washington, D.C. 20005 202.942.1000 Fax 202.942.1125 5.70.27 Subject: Enbrel Page: 1 of 8 Last Review Date: March 16, 2018 Enbrel Description Enbrel (etanercept),
More informationLupus. Fast facts. What is lupus? What causes lupus? Who gets lupus?
Lupus Systemic lupus erythematosus, referred to as SLE or lupus, is sometimes called the "great imitator." Why? Because of its wide range of symptoms, people often confuse lupus with other health problems.
More information2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients
2017 PERIOPERATIVE MEDICINE SYMPOSIUM Peri-operative use of immunosuppression in rheumatology patients Dr Alberta Hoi Rheumatologist MBBS, FRACP, PhD NEW ERA IN MUSCULOSKELETAL MEDICINE New drugs - Biologics,
More informationMEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib)
MEDICATION GUIDE XELJANZ (ZEL JANS ) (tofacitinib) Read this Medication Guide before you start taking XELJANZ and each time you get a refill. There may be new information. This Medication Guide does not
More informationMEDICATION GUIDE. (tocilizumab)
MEDICATION GUIDE ACTEMRA (AC-TEM-RA) (tocilizumab) Read this Medication Guide before you start ACTEMRA and before each infusion. There may be new information. This Medication Guide does not take the place
More information